Skip to main content
Edwards Lifesciences Logo

보도 자료

newsroom banner image
newsroom banner image
newsroom banner image
First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards Valves
Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR
Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability
Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE
CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION
TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION
FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE
EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK
EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE
DATA FROM BENCHMARK REGISTRY DEMONSTRATE IMPROVED TAVR EFFICIENCY WITH PRESERVED PATIENT SAFETY
EDWARDS' AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATA
EDWARDS HIGHLIGHTS NEW DATA AT ACC RELATED TO LIFETIME MANAGEMENT OF AORTIC STENOSIS
EDWARDS LIFESCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE
EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT
EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL
EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION
EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK
EDWARDS LIFESCIENCES TO PRESENT AT THE BERNSTEIN 38TH ANNUAL STRATEGIC DECISIONS CONFERENCE
EDWARDS MITRIS RESILIA VALVE RECEIVES FDA APPROVAL FOR MITRAL REPLACEMENT SURGERIES
EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR TRANSCATHETER PULMONIC VALVE REPLACEMENT
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program
TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis
Edwards Lifesciences initiates $100 million social impact investment fund to advance racial equity
Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVR
Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff
Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR
Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR
Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years
Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
Edwards' KONECT RESILIA Aortic Valved Conduit Receives FDA Approval For Complex Aortic Valve Surgeries
Edwards Lifesciences Agrees To Global Transcatheter Litigation Settlement With Abbott
Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair
Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials In Response To Hospitals' Focus On COVID-19
Edwards Lifesciences To Present At The Cowen 40th Annual Healthcare Conference
Edwards Lifesciences' Every Heartbeat Matters Philanthropic Initiative Expanding To Reach More Patients
Edwards Lifesciences To Present At The 38th Annual J.P. Morgan Healthcare Conference
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients
Edwards Lifesciences To Present At The 2019 Wells Fargo Healthcare Conference
Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation
Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020
Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
Edwards Receives Clearance For HemoSphere Platform With Intelligent Decision-Support Tools
Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve
Edwards Lifesciences' Philanthropy Exceeds Every Heartbeat Matters Goal To Impact One Million Underserved People Ahead Of Schedule
Edwards Lifesciences To Present At The 13th Annual Wells Fargo Healthcare Conference
Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth Conference
Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions Conference
Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve
Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims Invalid
Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe
Edwards Lifesciences To Present At The Cowen 38th Annual Health Care Conference
Edwards Lifesciences To Present At The 36th Annual J.P. Morgan Healthcare Conference

연락처

투자자

(+1).949.250.6826

Mark Wilterding
(SVP, 투자 홍보)

미디어

(+1).949.250.5070

Sarah Huoh
(SVP, 글로벌 커뮤니케이션)